Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGH8WV)

Drug Name

MeTRH Drug Info

Synonyms

38983-06-1; His(1-methyl)-TRH; [3H]MeTRH; (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]-1-methyl-5-oxopyrrolidine-2-carboxamide; [3H]Me-thyrotropin-releasing hormone; AC1NSKDH; His(1-methyl)-thyrotropin-releasing hormone; GTPL2141; GTPL2137; CTK1A8669; DTXSID50415524; pGlu-His(1(tau)-methyl)-ProNH2; [3H]pGlu-His(1(tau)-methyl)-ProNH2; L-Prolinamide, 1-methyl-5-oxo-L-prolyl-L-histidyl-; His(1-methyl)-TRH; pGlu-His(1(t)-methyl)-ProNH2

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5311291
CAS Number: CAS 38983-06-1
TTD Drug ID: DMGH8WV

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Thyrotropin-releasing hormone receptor (TRHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
protirelin	DMGN5QD	Central nervous system disease	8A04-8D87	Approved	[3]
AZETIRELIN	DMLY9F1	Pain	MG30-MG3Z	Phase 3	[4]
MONTIRELIN TETRAHYDRATE	DM31OGZ	Pain	MG30-MG3Z	Discontinued in Preregistration	[5]
Posatirelin	DML6EWH	Neurodegenerative disorder	8A20-8A23	Discontinued in Phase 3	[6]
JTP-2942	DM29C6S	Cognitive impairment	6D71	Discontinued in Phase 2	[7]
MK-771	DM4YQV0	Discovery agent	N.A.	Investigative	[8]
CORYMBONE B	DM463S2	Discovery agent	N.A.	Investigative	[9]
C4X-101	DM5971G	Endocrine disease	5B3Z	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thyrotropin-releasing hormone receptor (TRHR)	TT4J8MF	TRFR_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2141).
2	Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice. Neuropsychopharmacology. 2013 May;38(6):950-6.
3	Company report (takeda)
4	Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II. In situ and in vitro absorption characteristics of azetirelin from the rat intestine. Biol Pharm Bull. 1995 Jul;18(7):976-9.
5	Montirelin hydrate (NS-3), a TRH analog, improved the disturbance of consciousness caused by head concussion and pentobarbital in mice. Nihon Yakurigaku Zasshi. 1996 May;107(5):237-45.
6	TRH analogs at Gedeon Richter Ltd.: highlights of experimental and clinical efficacy of posatirelin. Acta Pharm Hung. 2002;72(1):62-8.
7	Effect of JTP-2942, a novel thyrotropin-releasing hormone analogue, on pentobarbital-induced anesthesia in rats. Eur J Pharmacol. 1995 Mar 24;276(1-2):177-82.
8	TRH analog MK-771 reverses neurochemical and learning deficits in medial septal-lesioned rats. Peptides. 1989 Jan-Feb;10(1):121-4.
9	Corymbones A and B, phloroglucinols with thyrotropin releasing hormone receptor 2 binding affinity from the flowers of Corymbia peltata. J Nat Prod. 2008 May;71(5):881-3.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 363).